Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-119-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
The data reported here are for the structural analogues DNNSA and CaDNNSA.
A GLP OECD 422 study indicated clinical biochemistry effects at 298 mg/kg/day and established a NOAEL at 95 mg/kg/day. The effects seen on the GI tract (hyperkeratosis of the forestomach epithelium, mucosal hyperplasia and increased severity of lymphogranulocytic inflammation in the caecum and increased amounts of mucus in the large intestines) are most probably related to acidic nature of DNNSA. In addition effects on spleen. liver and bone marrow were reported.
In a study that is performed according to OECD 408 with the calcium salt of the substance, 6/10 females in the highest dose group died, showing alterations in the gastro-intestinal tract, a small thymus and bone marrow atrophy. The surviving females at 1000 mg/kg bw showed similar effects and a reduced body weight (gain). The effects on the gastro-intestinal tract also became apparent in males at 300 and 1000 mg/kg bw. These animals also had a reduced body weight (gain). Other effects included changes in numbers of white blood cells, lymphocytes, platelets as well as effects on several biochemical parameters. Macroscopy and histopathology indicated that next to the GI-tract mainly the thymus and bone marrow could be considered as potentially affected in males at 300 mg/kg bw and above and in females at 1000 mg/kg bw. The NOAEL as derived from this study is 100 mg/kg bw.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- High Quality GLP study following current guidelines.
- System:
- gastrointestinal tract
- Organ:
- bone
- thymus
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Treatment of male and female Wistar rats with DNNSA by oral gavage in a study according to OECD 422 at dose levels of 95, 298 and 893 mg/kg bw revealed parental toxicity at 298 and 893 mg/kg bw. At 95 mg/kg, no toxicologically relevant effects were noted in any of the parameters examined. In a 90 -day study on the calcium salt of the substance 6/10 females at 1000 mg/kg bwdied, showing alterations in the gastro-intestinal tract, a small thymus and bone marrow atrophy. The surviving females at 1000 mg/kg bw showed similar effects and a reduced body weight (gain). The effects on the gastro-intestinal tract also became apparent in males at 300 and 1000 mg/kg bw. These animals also had a reduced body weight (gain). Other effects included changes in numbers of white blood cells, lymphocytes, platelets as well as effects on several biochemical parameters. Macroscopy and histopathology indicated that next to the GI-tract mainly the thymus and bone marrow could be considered as potentially affected in males at 300 mg/kg bw and above and in females at 1000 mg/kg bw.
Justification for selection of repeated dose toxicity via oral
route - systemic effects endpoint:
A well-conducted GLP OECD 408 study without significant deficiencies
that established a dose-response relationship and a NOAEL.
Justification for selection of repeated dose toxicity inhalation -
systemic effects endpoint:
Due to low vapor pressure (3.3E-5 Pa at 20 °C) and high boiling
point (> 50 °C), the inhalation route is not considered to be a relevant
exposure route to human. In addition, the data of acute toxicity by oral
is available and sufficient for assessment of acute toxicity of test
substance. Thus, the acute inhalation toxicity study can be waived.
Justification for selection of repeated dose toxicity inhalation -
local effects endpoint:
Due to low vapor pressure (3.3E-5 Pa at 20 °C) and high boiling
point (> 50 °C), the inhalation route is not considered to be a relevant
exposure route to human. In addition, the data of acute toxicity by oral
is available and sufficient for assessment of acute toxicity of test
substance. Thus, the acute inhalation toxicity study can be waived.
Justification for selection of repeated dose toxicity dermal -
systemic effects endpoint:
It is considered that exposure via the oral route is considered a
worst case exposure whereby the systemic availability of the substance
is considered to be maximised. Exposure via the dermal route is expected
to be considerably less than via the oral route due to lack of
absorption under expected exposure conditions. In addition, the acute
dermal study shows that no adverse effects were observed. The data of
acute toxicity by oral is available and sufficient for assessment of
acute toxicity of test substance. Thus, the acute dermal toxicity study
can be waived.
Justification for selection of repeated dose toxicity dermal - local
effects endpoint:
It is considered that exposure via the oral route is considered a
worst case exposure whereby the systemic availability of the substance
is considered to be maximised. Exposure via the dermal route is expected
to be considerably less than via the oral route due to lack of
absorption under expected exposure conditions. In addition, the acute
dermal study shows that no adverse effects were observed. The data of
acute toxicity by oral is available and sufficient for assessment of
acute toxicity of test substance. Thus, the acute dermal toxicity study
can be waived.
Justification for classification or non-classification
In the OECD 422 study, side effects were seen at 298 mg/kg bw/d (mid dose group) whereas no effects occurred at 95 mg/kg bw/d (low dose group). The most prominent effects were the mortalities at 893 mg/kg/day (4 males and 1 female) and at 298 mg/kg/day (1 female). Surviving animals in both treatments showed some of the same clinical signs as those in the animals sacrificed. Thus, the NOAEL was set to 95 mg/kg bw/d. In the 90 day oral repeated dose toxicity study with the calcium salt mortality was observed at 1000 mg/kg bw in females. At 300 and 1000 mg/kg in males and at 1000 mg/kg bw in females effects on body weight, GI-tract alterations and histopathlogical changes in the thymus and bonemarrow became apparent. These effects are not considered leading to a classification for specific target organ systemic toxicity, repeat exposure according to CLP (Regulation EC No 1272/2008).
.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
